Clearpoint Neuro Inc

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ClearPoint Neuro reports revenue growth, faces margin pressures in 2022

ClearPoint Neuro's financial performance in 2022 showed revenue growth but faced margin pressures and increased operating expenses.
The company's strengths lie in revenue growth projections, successful product launches, and cost-saving initiatives.
Challenges include post-COVID operational disruptions, supply chain concerns, and achieving cash breakeven targets.
Opportunities exist in R&D investments, international expansion, and maintaining an optimistic outlook for future growth.

ClearPoint Neuro reports Q1 growth, targets $50M revenue by 2025

ClearPoint Neuro Inc's Q1 performance reflects steady revenue growth and strategic investments to drive future expansion and innovation.
While facing challenges in certain revenue segments and margin decline, the company's strong growth strategy and focus on key areas present opportunities for sustained success.
With a clear roadmap to achieve revenue targets, expand partnerships, and launch new products, ClearPoint is poised for continued growth and market leadership in the neurosurgery sector.

ClearPoint Neuro reports record revenue and growth strategy focus

ClearPoint Neuro Inc's Q2 2023 earnings call highlighted record revenue, growth pillars, and operational efficiency improvements. Challenges include installation barriers and regulatory expansions, while opportunities lie in neuro-oncology expansion and pharma partnerships. The company aims for cash flow breakeven by 2025 and emphasizes long-term pharma relationships.

ClearPoint Neuro reports improved Q3 performance amidst strategic growth plans

ClearPoint Neuro's Q3 2023 performance showed improvements in operational cash burn and revenue growth in key segments, despite challenges in gross margin and operating expenses.
The company's strategic focus on innovation, patient outcomes, and market expansion presents opportunities for sustained growth and competitiveness in the healthcare sector.
While facing challenges in cost management and market access, ClearPoint Neuro is well-positioned to leverage opportunities in new revenue streams, product launches, and operational enhancements.
Overall, ClearPoint Neuro's commitment to improving patient outcomes, expanding market reach, and driving innovation underscores its potential for future success and growth.

ClearPoint Neuro reports robust Q4 earnings, eyes growth opportunities

ClearPoint Neuro's strong Q4 performance and revenue growth in 2023 position the company well for 2024. Despite challenges with EU MDR certification, ClearPoint is investing in partnerships to overcome regulatory hurdles. Opportunities for growth include new product releases and expanding market presence.

ClearPoint Neuro reports 41% revenue growth in Q1 2024

ClearPoint Neuro's Q1 2024 earnings call showcased robust revenue growth, controlled expenses, and a strategic focus on key growth areas. The company's optimistic outlook for 2024 is supported by strong demand from pharmaceutical partners and expansion initiatives.

ClearPoint Neuro reports record revenue growth and raises full-year guidance

ClearPoint Neuro's Q2 2024 performance reflects robust revenue growth and a solid financial position.
The company's focus on key growth pillars and increased revenue guidance for the year signal a positive outlook for future expansion.
While challenges in cost management and market competition exist, ClearPoint Neuro's strengths and opportunities position it well for sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced its Swedish partner, Clinical Laserthermia Systems (CLS), has received 510(k) clearance for its laser which the Company plans to commercialize as the ClearPoint Prism™ Neuro Laser Therapy System.

ClearPoint Neuro Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy System

SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team.

ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

SOLANA BEACH, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has obtained 510(k) clearance for version 2.1 of the ClearPoint Neuro Navigation software.

ClearPoint Neuro Announces FDA Clearance for Software Version 2.1

Revenue growth rebounded strongly due to its acceleration in B&DD and capital equipment and software revenue. The company marks its first milestone with its FDA approval with PTC-AADC, with certainly more to come.

ClearPoint Neuro: Continuous Great Execution

Coupang

Here are two interesting companies under $20.

2 Stocks Under $20 to Watch

Shares have lost 20% of their value since the initial public offering in February of last year. The company is well-positioned as a "picks and shovels" play to pharmaceutical partners addressing neurological indications.

ClearPoint Neuro: Picks & Shovels Galore

ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Joe Burnett - Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital William Wood - B. Riley Operator Greetings, and welcome to the ClearPoint Neuro Second Quarter 2022 Financial Results Conference Call.

ClearPoint Neuro, Inc. (CLPT) CEO Joe Burnett on Q2 2022 Results - Earnings Call Transcript

Record Quarterly Revenue Achieved; Company Reaffirms 2022 Revenue Forecast Record Quarterly Revenue Achieved; Company Reaffirms 2022 Revenue Forecast

ClearPoint Neuro Reports Second Quarter 2022 Results

CLPT has been growing revenues steadily and has a large addressable market. It also has a very strong moat due to the nature of the FDA approval process.

ClearPoint Neuro:  A 'Picks And Shovels' Biotech Company

First Gene Therapy Approved for Direct Infusion into the Brain will be Administered with ClearPoint's SmartFlow® Neuro Cannula First Gene Therapy Approved for Direct Infusion into the Brain will be Administered with ClearPoint's SmartFlow® Neuro Cannula

ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ - First Disease-Modifying Treatment for AADC Deficiency

SOLANA BEACH, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain today congratulates partner Neurona Therapeutics on dosing the first patient in their Phase 1/2 clinical trial of its lead program NRTX-1001, in a first-in-human epilepsy study. Harish Babu, MD, PhD, Assistant Professor of Neurosurgery at SUNY Upstate Medical University administered the first dose.

ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy

ClearPoint Neuro, Inc. (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ClearPoint Neuro, Inc. (CLPT) Surges 7.6%: Is This an Indication of Further Gains?

First Gene Therapy Directly Infused into the Brain to be Administered with ClearPoint's SmartFlow® Cannula First Gene Therapy Directly Infused into the Brain to be Administered with ClearPoint's SmartFlow® Cannula

ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency

SOLANA BEACH, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it will present investigational research and exhibit at the 25 th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington, DC.

ClearPoint Neuro to Present Investigational Research and Exhibit at the American Society of Gene & Cell Therapy Annual Meeting in Washington, DC

ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Marc Weisenberger - B. Riley Securities Operator Greetings and welcome to the ClearPoint Neuro, Inc. First Quarter 2022 Financial Results Conference Call.

ClearPoint Neuro, Inc. (CLPT) CEO Joe Burnett on Q1 2022 Results - Earnings Call Transcript

SOLANA BEACH, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2022.

ClearPoint Neuro Reports First Quarter 2022 Results

Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room

ClearPoint Neuro Announces FDA Clearance of the SmartFrame Array™ Version 1.1

SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 first quarter on Wednesday, May 11, 2022, after the market close.

ClearPoint Neuro to Announce First Quarter 2022 Results May 11, 2022

SOLANA BEACH, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the B. Riley Securities Disruptive Biotech Enabling Technologies Mini Conference on Thursday, April 7, 2022 at 2:30 p.m. Eastern Time.

ClearPoint Neuro to Present at the B. Riley Securities Disruptive Biotech Enabling Technologies Mini Conference

ClearPoint Neuro's (CLPT) CEO Joe Burnett on Q4 2021 Results - Earnings Call Transcript

Company Reports Record Revenues Company Reports Record Revenues

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2021 Results

Company to Hold Earnings Call on March 1, 2022 Company to Hold Earnings Call on March 1, 2022

ClearPoint Neuro Reports Fourth Quarter and Full Year 2021 Preliminary Revenue Results and Guidance for Full Year 2022 Revenue

Even though elective procedures are returning to the pre-pandemic level, the rise of the Omicron variant resurgence may continue to impact the case volume in the upcoming quarters. ClearPoint Neuro is working with 40 biology partners as of Q3'21, and with 100 potential partners in the intracranial and spine segment, this increases the odds of multiple commercialization.

ClearPoint Neuro: Underlying Growth Potential Concealed By COVID

SOLANA BEACH, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will participate at the H.C. Wainwright BIOCONNECT Virtual Conference. A pre-recorded company presentation will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on January 10, 2022.

ClearPoint Neuro to Participate at the H.C. Wainwright BIOCONNECT Virtual Conference

SOLANA BEACH, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner Blackrock Neurotech for receiving Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its groundbreaking MoveAgain Brain Computer Interface (BCI) system.

ClearPoint Neuro Congratulates Blackrock Neurotech on Receiving Breakthrough Device Designation from the FDA for the MoveAgain Brain-Computer Interface System

News for Clearpoint Neuro Inc Stock (CLPT)